Growth Metrics

Eli Lilly (LLY) Deferred Taxes (2016 - 2026)

Eli Lilly filings provide 18 years of Deferred Taxes readings, the most recent being $1.5 billion for Q1 2026.

  • On a quarterly basis, Deferred Taxes rose 277.04% to $1.5 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $2.8 billion, a 0.11% change, with the full-year FY2025 number at $1.7 billion, down 36.38% from a year prior.
  • Deferred Taxes hit $1.5 billion in Q1 2026 for Eli Lilly, up from $748.1 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $1.5 billion in Q1 2026 to a low of -$501.4 million in Q3 2025.
  • Median Deferred Taxes over the past 5 years was $559.4 million (2023), compared with a mean of $611.4 million.
  • Biggest five-year swings in Deferred Taxes: surged 4967.31% in 2023 and later crashed 216.66% in 2025.
  • Eli Lilly's Deferred Taxes stood at -$10.4 million in 2022, then surged by 4967.31% to $506.2 million in 2023, then soared by 90.95% to $966.6 million in 2024, then dropped by 22.61% to $748.1 million in 2025, then skyrocketed by 97.57% to $1.5 billion in 2026.
  • The last three reported values for Deferred Taxes were $1.5 billion (Q1 2026), $748.1 million (Q4 2025), and -$501.4 million (Q3 2025) per Business Quant data.